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During chemo- and radiation therapy, the balance between epithelial cell proliferation, differentiation, and cell death at the villus tip
is disrupted by premature death of dividing epithelial cells. This will subsequently lead to the onset of mucosal barrier injury in the
whole gastrointestinal tract. Up till now there is no validated method to treat side effects occurring due to therapy. An approach to
manage this side effect might be to reversibly arrest growth of epithelial stem cells during therapy using Transforming Growth
Factor-b2. A Transforming Growth Factor-b2 enriched fraction prepared from bovine milk was shown to protect small intestinal
epithelial cells against cell cycle speciﬁc chemotherapeutic agents by arresting the cells in G1-phase. Secondly, in a rat model for
induced small intestinal damage, oral supplementation of rats exposed to methotrexate with the Transforming Growth Factor-b2
enriched fraction signiﬁcantly reduced the chemotherapy-associated weight loss and ileal villus atrophy by reducing cell
proliferation in the normal stem cell population. Thus oral supplementation with a bovine milk fraction enriched for Transforming
Growth Factor-b2 attenuated the side effects of chemotherapy in the small intestine in rats.
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Anti-cancer chemotherapy and radiation treatment relies primarily
on the high proliferation rate of tumour cells. Stem cells of the
gastrointestinal tract are among the most rapidly proliferating cells
in the body, and therefore also affected by this anti-tumour
approach targeted towards proliferating cells. Entrocyte function
in rats has been shown to be effected adversely by methotrexate
(MTX) resulting in altered intestinal permeability (Taminiau et
al, 1980) which has a counterpart in humans (Keefe et al, 1997;
Parrilli et al, 1989). The several complications, i.e. vomiting, nausea
and mucosal barrier injury (Sonis, 1998; Blijlevens et al, 2000)
result from loss of integrity of the intestinal barrier which is a
key element in preventing inappropriate uptake and transport of
macromolecules, bacteria and enteric toxins. To date, there is still
no validated method to treat the side effects of anti-cancer treat-
ment.
Speciﬁc cell cycle arrest of rapid proliferating epithelial stem
cells is a promising approach to protect the mucosa from the direct
side effects of anti-cancer treatment. Transforming Growth Factor-
b3 (TGF-b3) has been shown to prolong or arrest the cell cycle of
epithelial cells in the G1-phase thereby providing protection in
vitro against cell-cycle speciﬁc chemotherapeutic agents that act
predominantly in the S- or M-phase of the cell cycle (McCormack
et al, 1997). Topical administration of recombinant human TGF-b3
has also been shown to attenuate the oral mucositis induced in
hamsters by 5-Fluorouracil with a concomitant reduction in weight
loss and shorter duration of oral mucositis (Sonis et al, 1997; Spij-
kervet and Sonis, 1998). It has been suggested that this protection
is mediated by the inhibition of proliferation of basal epithelial
cells during exposure to chemotherapy. Positive results have been
obtained in humans using mouthwashes containing recombinant
TGF-b3 (Wymenga et al, 1999), indicating a promising treatment
against the oral complications of anti-cancer therapy. Administra-
tion of recombinant TGF-b3 directly into the small intestine of
mice had a protective effect during radiation (Potten et al, 1997)
by reducing stem cell cycling (Booth et al, 2000). To our know-
ledge however, no study has been done investigating the
potential protective effects of orally administrated TGF-b2 originat-
ing from a natural source. We therefore set out to determine the
efﬁcacy in vitro and in vivo of TGF-b2 in protecting intestinal
epithelial cells from damage induced by methotrexate (MTX).
MATERIALS AND METHODS
Cells
The small intestine rat epithelial cell line (IEC-6) was obtained
from ATCC (Rockville, MD, USA) and cultured at 378C and 5%
CO2 in Dulbecco’s modiﬁed Eagle’s medium adjusted to contain
1.5 g l
71 sodium bicarbonate and 4.5 g l
71 glucose and supple-
mented with 50 000 IU l
71 penicillin, 50 mg l
71 streptomycin
and 10% heat inactivated foetal calf serum (FCS) all obtained from
Gibco BRL. Cells were used between passage 19 and 35.
TGF-b2 enriched fraction
TGF-b2 enriched fraction was obtained from bovine milk by puri-
ﬁcation with cationic exchange chromatography (DMV
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750 mgg
71 TGF-b protein consisting for *90% TGF-b2 and
*10% TGF-b1. No detectable levels of TGF-b3 could be measured
by ELISA techniques. Forty-nine per cent of the TGF-b in the frac-
tion was unbound and active as measured in a bioassay.
Proliferation assay
IEC-6 cells were cultured for 72 h in a 96-well microtiter plate
(Costar, Schiphol, The Netherlands) with a concentration range
of 0.25–2.5 ng ml
71 of recombinant TGF-b3 or TGF-b2 in the
enriched fraction. Sixteen hours before the end of the assay
10 mM 5-bromo-2'-deoxyuridine (BrdU) was added to the wells,
and the incorporation was visualised according to the manufacture
protocol (Boehringer Mannheim), and measured at 450 nm.
Cell death/cell cycle arrest
To establish the capacity of TGF-b2 enriched fraction to arrest
cells in growth, ﬂowcytometry analyses were done. IEC-6 cells
were cultured in a 6 well plate and incubated together with
2.5 mgm l
71 cytosine arabinoside (Ara-C, cytarabine; Sigma,
Zwijndrecht, The Netherlands) for 48 h with or without TGF-b2
enriched fraction (2 ng ml
71 of TGF-b2) or 2 ng ml
71 recombi-
nant TGF-b3. The cells were then harvested and prepared for
ﬂowcytometry as described previously (Fraker et al, 1995). Brieﬂy,
cells were trypsinised, washed twice with PBS containing 0.1%
EDTA (PBS-E) then ﬁxed in 70% ethanol for 45 min at 7208C.
Cellular DNA was labelled with propidium iodide by washing
the cells twice with PBS-E and incubating them with PBS-E
containing propidium iodide (5 mgm l
71) and RNA-se
(1 mgm l
71) for 45 min in the dark. The cell preparations were
analysed using a ﬂowcytometer (Coulter, Mijdrecht, The Nether-
lands) and were separated into three populations according to
their ﬂuorescence intensity i.e. DNA content N=1 represent cells
in the G1-phase, N=2 mitotic G2-phase and apoptotic cells
contain N51 amount of DNA.
In vitro cell viability assay
IEC-6 cells were harvested in the exponential phase of growth,
deposited in 96-well microtitration plates (Costar, Schiphol, The
Netherlands) and cultured for 24 h with or without TGF-b2
enriched fraction (2 ng ml
71 TGF-b2). A concentration range of
0.05–0.13 mgm l
71 Cytosine Arabinoside (Ara-C) (Sigma, Zwijn-
drecht, The Netherlands) was subsequently added to the cells and
incubated for 72 h at 378C and 5% CO2. The cells were then
washed three times with PBS and incubated in normal medium
for 48 h at 378C and 5% CO2. After 4 h incubation at 378C with
50 ml tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-[(sulphenylami-
no)carbonyl]-2H-tetrazolium-hydroxide] (XTT) solution as
provided in the kit from Boehringer Mannheim, formation of
the formazan dye by metabolically active cells was measured at
490 nm. To establish that TGF-b2 is the active compound in the
fraction, neutralising monoclonal mouse anti-TGF-b2 (Genzyme
Diagnostics, Leuven, Belgium) was added at a concentration of
0.1 mg ml
71 for 1 h, prior to testing in the cellular viability assay
as described above.
In vitro protease degradation assay
In vivo protein degradation in the stomach was simulated by incuba-
tion of the TGF-b2 fraction with a buffer containing 53 mmol l
71
NaCl, 0.7 mmol l
71 CaCl2, 15 mmol l
71 KCl, 71 mmol l
71
NaHCO3,7 0mgm l
71 pepsin from bovine pancreas (Sigma, Zwijn-
drecht, The Netherlands) and 70 mgm l
71 lipase (Sigma,
Zwijndrecht, The Netherlands) at pH 3.0 for 60 min at 378C. After
incubation, the enzymes were inactivated by neutralising with NaOH
to pH 7.0, and stored at 7208C until required for analysis. The
remaining cytoprotective capacity of the fractions after protein degra-
dation was tested in the cell viability assay as described before.
MTX-animal model
The animal experiments were approved by the Animal Care and
Ethics Committee (DEC, The Netherlands) and were performed
according to the UKCCCR ‘Guidelines for the Welfare of Animals
in Experimental Neoplasia’ (1998). Eight-week old female Wag/Rij
rats (Charles River, Wiga, Germany) with a weight average of
119.0+4.5 g were kept in pairs in conventional cages and in a
12 h reversed light/dark cycle, with free access to chow and water.
All rats switched to a semi-synthetic diet (Hope-farms Woerden,
The Netherlands) containing 1 mg kg
71 folic acid 7 days before
starting the experiments. At the same time they were trained to
expect to be given a supplement twice daily at 0900 h and
1600 h using a placebo containing 2.5% casein, 2.5% sucrose and
strawberry vanilla ﬂavour dissolved in water, which was added in
addition to normal chow. Placebo and semi-synthetic diet were
given to the animals until the end of the experiment. Supplementa-
tion of TGF-b2 enriched fraction (5 mg TGF-b2/rat/day) was
started on day 71 until day 1. Two groups of rats (n=4 per group)
supplemented with placebo or the TGF-b2 enriched fraction were
injected i.v. on day 0 with 20 mg kg
71 body weight MTX (Leder-
trexate SP Forte, AHP Pharma Hoofddorp, The Netherlands),
followed by a second MTX injection of 10 mg kg
71 body weight
24 h later. Two groups of control animals (n=4 per group) were
injected with a similar volume of 7% saline solution and supple-
mented with either placebo or the TGF-b2 enriched fraction.
Body weight was monitored daily. In a pilot experiment (data
not shown) it was found that maximal intestinal damage occurred
on day 4, thus small intestine of each animal was collected subse-
quently at this time thereafter. Rats were injected with 50 mg kg
71
body weight BrdU i.p. 16 h before tissue collection to determine
the effects on cellular proliferation and to establish the effect of
the TGF-b2 enriched fraction on intestinal epithelial cell prolifera-
tion two additional groups (n=4) of animals were scariﬁed 16 h
after the last supplementation with the TGF-b2 enriched fraction.
Animals were killed under sedation and segments of the small
intestine were removed for immunohistological staining and
morphological examination. All segments were carefully rinsed
once with cold PBS and ﬁxed in 4% paraformaldehyde at pH 7.4
(Sigma, Zwijndrecht, The Netherlands) for 16 h, dehydrated and
embedded in parafﬁn.
Immunohistology
To examine morphological damage in the small intestine, 5 mm
sections were cut transversely to visualise the entire villus, subse-
quently rehydrated and stained with 1 mg ml
71 Haematoxylin
(Sigma, Zwijndrecht, The Netherlands) and 10 mg ml
71 Eosin
(Sigma, Zwijndrecht, The Netherlands). BrdU incorporation was
detected using 0.5 mgm l
71 mouse monoclonal anti-BrdU (Boeh-
ringer Mannheim) followed by incubation with 1.5 mgm l
71 anti-
mouse IgG (Vector Laboratories), which was visualised after thor-
ough washings with PBS using ABC-complex (Vector Laboratories)
and 3,3'-diaminobenzidine tablets dissolved in H2O (Sigma, Zwijn-
drecht, The Netherlands). Villus lengths, crypt depths and BrdU-
incorporation were measured with an image analysis program
(Zeiss KS300). At leased 15 cross-sections per rat were analysed
blindly by two independent researchers.
Statistical analysis
The Student two sided t-test was used to analyse cellular viability
(expressed as a per cent of control) between cell cultures treated with
chemotherapeutic agents and untreated control cultures, villus height
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British Journal of Cancer (2002) 87(1), 113–118 ã 2002 Cancer Research UKand crypt depth measurements (mm) and body weight (expressed as
per cent of day 0 control) between the groups of animals supplemen-
ted with TGF-b2 enriched fraction and those that were not. P
values50.05 were considered statistically signiﬁcant.
RESULTS
The proliferation inhibition capacity of the TGF-b2
enriched fraction
A dose dependent proliferation inhibition up to 56+5% was seen
when IEC-6 cells were incubated with 2.0 ng ml
71 TGF-b2 in the
enriched fraction. The in vitro proliferation inhibition capacity of
the TGF-b2 enriched fraction is comparable to equal concentrations
of recombinant TGF-b3 (Figure 1A). When IEC-6 cells were incu-
bated with recombinant TGF-b3 a decrease of 17.2% of the
proliferating cells was seen in the ﬂowcytometry analysis (Figure
1B), which resulted in an increase in the G1-phase population. A
comparable shift of 16.4% from proliferating cells to the G1-phase
was seen with the TGF-b2 enriched fraction. These results indicated
that proliferation of the IEC-6 cells is inhibited by the TGF-b2
enriched fraction, due to growth arrest in the G1-phase.
Protective effect of TGF-b2 enriched fraction on cell
cycle-speciﬁc drug-induced damage
An Ara-C dependent increase was seen in the fraction of apopotic
cells on ﬂowcytometry (Figure 1B) and a concentration dependent
decline was seen in the cellular viability measured using XTT
reagent (Figure 2A). In both assays inhibition of the toxic effect
was seen when cells were incubated with TGF-b2 enriched frac-
tion in comparable efﬁciency as recombinant TGF-b3. The IC-
50 for with Ara-C is 0.07 mgm l
71 in the absence of TGF-b2
enriched fraction, whereas treatment in presence of the TGF-b2
enriched fraction gave a six-fold higher IC-50 value (0.43 mgm l
71)
indicating a higher cell survival. Even with high concentrations of
Ara-C (2.5 mgm l
71), 30% of the cells remained viable when
simultaneously incubated with the TGF-b2 enriched fraction. Incu-
bation with TGF-b2 enriched fraction also showed a diminished
reduction in cell viability of 28+7% when IEC-6 cells were incu-
bated with MTX, yet another cell cycle speciﬁc drug (Figure 2B).
The bovine milk fraction although enriched for TGF-b2, might
still contain other active proteins. The cytoprotective effect of the
TGF-b2 enriched fraction was completely blocked by pre-incuba-
tion of the fraction with a speciﬁc monoclonal anti-TGF-b2
antibody. There was as little as 1% difference seen between the cells
incubated with TGF-b2 enriched fraction which was neutralised for
TGF-b2 and the cells treated with high doses of Ara-C alone (see
Figure 2A).
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Figure 1 (A,B) TGF-b2 enriched fraction and recombinant TGF-b3
comparably inhibit proliferation and protect cells against Ara-C induced
toxicity by induction of G1-phase arrest. In Figure 1A, BrdU incorporation
into IEC-6 cells incubated for 48 h with a concentration range of recombi-
nant TGF-b3 (closed triangles) or the TGF-b2 enriched fraction (open trian-
gles) is shown. The data represent mean+s.d. of three independent
experiments. In Figure 1B, G1-phase arrest is detected by ﬂowcytometry-
analysis of propidium iodide labelled IEC-6 cells incubated with recombinant
TGF-b3 or the TGF-b2 enriched fraction in the presence or absence of Ara-
C. A total of 10000 cells were counted and divided into three sections, of
which G1-phase represents cells with N amount of DNA, G2-phase repre-
sents the cells in proliferating phase i.e. containing N2 amount of DNA and
the remaining dying cells (amount 5N).
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Figure 2 (A,B) Epithelial cells are protected against cell cycle speciﬁc
drug, due to TGF-b2 present in TGF-b2 enriched fraction. Cell viability
of IEC-6 cells after treatment with a concentration range of Ara-C (A)
or MTX (B), incubated with (closed triangle) or without (closed square)
TGF-b2 enriched fraction is shown. The open triangles (A) show cells,
which were incubated with TGF-b2 enriched fraction after blocking of
TGF-b2 activity by pre-incubation with anti-TGF-b2 antibodies. Mean+s.d.
of three individual experiments is shown. Statistical differences between
viability of cells incubated with TGF-b2 enriched fraction after depletion
for TGF-b2 and control or TGF-b2 alone are indicated with #(P50.05)
or *(P50.01).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(1), 113–118Since the use of TGF-b2 enriched fraction in enteral nutrition was
examined, in an in vitro protease degradation (as described in Mate-
rials and Methods), the effect of intestinal transit and degradation
was evaluated. The remaining protective capacity of TGF-b2
enriched fraction against Ara-C induced toxicity was tested on the
IEC-6 cells after in vitro degradation with or without the presence
of casein. Without the presence of casein, the protective effect of
TGF-b2 enriched fraction was indeed decreased after in vitro degra-
dation to 3–4% and was totally diminished at higher concentrations
of Ara-C (Figure 3). Within the presence of casein however, the
protective effect of TGF-b2 enriched fraction remained intact after
the in vitro degradation, as it resulted in 21+3% cell viability left
after exposure to the high concentrations of Ara-C.
Protective effects of TGF-b2 enriched fraction in vivo
Throughout the entire small intestine MTX caused a shortening of
villus length, to a minimum of 0.2 mm was seen due to MTX toxi-
city (Figure 4A). In the duodenum the villus length was reduced
for 450%, in the jejunum for *40% and in the ileum a reduction
of *25% was detected. Supplementation with TGF-b2 enriched
fraction resulted in restoration of villus length throughout the
small intestine, and reached signiﬁcance (P50.05) in the ileum.
Villus length was reduced to 0.20+0.010 mm in the MTX treated
group and restored to 0.27+0.009 mm in the rats supplemented
with TGF-b2 enriched fraction, which equals the villus length in
the control rats (0.27+0.006 mm). However no signiﬁcant restora-
tion of villus atrophy seen after MTX treatment could be detected
in the duodenum or jejunum. Equal protective capacities of the
TGF-b2 enriched fraction were found in a second set of experi-
ments (data not shown). There was no effect seen on villus
length in control rats supplemented with TGF-b2 enriched fraction
(Figure 4A). The effect of MTX on the crypt depths is shown in
Figure 4B. No signiﬁcant effect of the TGF-b2 enriched fraction
supplementation could be detected in the crypt depth measure-
ments. The proliferation inhibition capacity of TGF-b2 enriched
fraction in vivo was estimated using BrdU incorporation during
the 16 h after the last supplementation. The BrdU length was
measured starting from the lowest BrdU positive crypt cell until
the highest BrdU positive cell migrated upon the villus axes. As
can been seen in Figure 4C a signiﬁcant (P50.05) inhibition of
proliferation could be detected in the ileum of rats supplemented
with the TGF-b2 enriched fraction compared to the control group.
All the control animals not receiving MTX, showed a steady
growth, which was unaffected by the supplementation of TGF-b2
enriched fraction (Figure 5). The rats however treated with MTX
showed a reduction in body weight already after the ﬁrst MTX
injection, resulting in difference of 15+2% with the control rats
at day 4. Supplementation with TGF-b2 enriched fraction during
MTX-treatment showed signiﬁcantly less reduction in body weight
than animals receiving placebo. The average body weight loss of the
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Figure 3 Diminished degradation of TGF-b2 due to the presence of
casein. Cell viability of IEC-6 cells after treatment with a concentration
range of Ara-C, of which the triangles represent treatment with TGF-b2
enriched fraction in an in vitro degradation assay, with (open) or without
(closed) casein present during the degradation. The controls with (open),
or without (closed) casein during the in vitro degradation assay, are repre-
sented by squares. Mean+s.d. of three separate experiments are shown.
*Indicates signiﬁcant differences with the negative control group (P50.01).
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Figure 4 (A,B,C) Supplementation of TGF-b2 enriched fraction re-
duced MTX induced villus atrophy due to stem cell proliferation inhibition.
Villus length (A) and crypt depths (B) were measured from different re-
gions in the small intestine at day 4 (n=4 per group) from rats receiving
either placebo (closed bars) or the TGF-b2 enriched fraction (open bars).
Statistical differences between the MTX control group only receiving place-
bo (hatched bars) or TGF-b2 enriched fraction (squared bars) are indicated
with #(P50.05). At least 60 microscopical measurements were made per
animal, at a magniﬁcation of 106 per rat. Bars show mean+s.d. for three
rats per group. In Figure (C), BrdU incorporation is shown as length in per
cent of control, measuring from the lowest BrdU positive crypt cell until the
highest BrdU positive cell upon the villus axis. Lengths were measured in
different regions of the small intestine at day two from four rats per group
receiving placebo (closed bars) or TGF-b2 enriched fraction (open bars).
Statistical differences are indicated with #(P50.05).
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MTX lost *10% of their body weight.
DISCUSSION
The small intestine maintains its function due to solid regulation
between epithelial cell proliferation, differentiation, and cell death
at the tip of the villus. During cytostatic chemotherapy, this
balance is disrupted by early cell death of the dividing stem cells
located in the crypt area. The present study shows that reducing
epithelial stem cell proliferation with TGF-b2 enriched milk frac-
tion from bovine origin protects the small intestinal epithelial
cell in vitro as well as in vivo from this premature death. It was
shown that the proliferation inhibition and cytoprotection of the
TGF-b2 enriched fraction is as effective as recombinant TGF-b3.
Furthermore immuno-neutralisation of TGF-b2 from the enriched
fraction proved that it is the TGF-b2 in the fraction that protects
the cells from cell-cycle speciﬁc drug-induced cell death, i.e. Ara-C
(Figure 2A) and MTX (Figure 2B) in vitro.
The protective mechanisms of growth factors used in animal
models of mucosal barrier injury are likely to be multifactoral.
The beneﬁt of pre-treatment with IL-11 and KGF has been shown
to modulate chemotherapy- or radiation-induced intestinal epithe-
lial injury (Potten, 1995, 1996; Farrell et al, 1998). The mechanism
whereby by IL-11 protects remains to be elucidated, but the protec-
tion mediated by TGF-b3 and KGF appears to be due to a
reduction in stem cell proliferation (Booth et al, 2000; Potten et
al, 2001). It is known that TGF-b3 reversibly arrests cell growth
in the G1-phase (Ko et al, 1998; Warner et al, 1999) which was
conﬁrmed for the TGF-b2 enriched fraction (Figure 1B). Reduced
proliferation of stem cells in vivo could also be detected after
supplementation of TGF-b2 enriched fraction showing limited
BrdU incorporation (Figure 4C). The signiﬁcant protection of
TGF-b2 enriched fraction seen on villus atrophy was limited to
the ileum, which was also the region where signiﬁcant reduction
of proliferation was found which indicates that protection is
brought about by reduced stem cell proliferation. Cell cycle speciﬁc
chemotherapeutic agents like Ara-C and MTX, inhibit speciﬁc
enzymes, leading to inhibition of DNA replication with S phase
speciﬁcity. These processes are reduced in cells with arrested
growth in the G1-phase by TGF-b2. In accordance with our results
epithelial cell proliferation stimulation during chemotherapy treat-
ment with IGF-1 is not favourable (Howarth et al, 1998). IGF-1
given after chemotherapy however resulted in an improved regen-
eration of small intestinal damage (Taylor et al, 2001). A study
done by Howarth et al (1996) using a growth factor enriched milk
fraction, which offered a slight protection against MTX induced
damage in vivo. TGF-b2 mediated G1-phase cell-cycle arrest could
not explain this protective effect since the fraction in question
actually stimulated the growth of epithelial cells in vitro rather than
arresting it.
The length of the villus of the duodenum is twice as long as that
of the ileum which might reﬂect a higher proliferating rate of the
epithelial cells, or the presence of more crypts containing stem cells
per villi in the duodenum than in the ileum. Equal damage to the
epithelial cells after exposure to MTX might explain why villus
length was reduced two-fold in the duodenum compared to the
ileum 4 days after MTX treatment. Strangely, however, unlike what
was seen in the ileum, villus length in the duodenum did not
return to its normal length after supplementation with the TGF-
b2 enriched fraction. Differences in TGF-b2 induced proliferation
inhibition efﬁciency might be related to binding with casein,
rendering it less free and therefore less active at the beginning of
the small intestine. This difference in villus restoration could also
reﬂect diversity in TGF-b receptor expression throughout the small
intestine. TGF-b3 and TGF-b1 show preferential binding to the RI
and RII signalling complex, whereas TGF-b2 requires RIII for
presentation to the RI/RII complex in order to initiate the cascade
of events leading to proliferation inhibition (Moustakas et al, 1993;
Henis et al, 1994). The expression of TGF-b receptors on epithelia
in the small intestine is currently under investigation. Although a
signiﬁcant restoration of the villus atrophy could only be detected
in the ileum, the weight of animals receiving TGF-b2 enriched frac-
tion did not show the same reduction as seen in MTX treated
animals receiving placebo which indicates that supplementation
of TGF-b2 enriched fraction attenuates small intestinal function
loss induced by MTX.
Safety and tolerability studies are required before oral supple-
mentation of TGF-b2 enriched fraction can be used clinically. In
addition, supplementation of any product reducing side effects of
anti-tumour treatment should not inﬂuence the treatment on
cancer cells negatively. A phase I study has already been conducted
to determine the safety and tolerability of recombinant TGF-b3
mouthwashes for prevention of chemotherapy induced oral muco-
sitis (Wymenga et al, 1999). In this study neither systemic
absorption nor development of TGF-b3 antibodies were observed.
It should be considered however, that the mouthwashes were not
ingested, which is essential for TGF-b2 which is intended for the
treatment of mucosal barrier injury throughout the whole gastroin-
testinal tract. On the other hand, a relative low dose of TGF-b2
could be used, since systemic uptake of TGF-b2 is not required
to protect the intestinal epithelial stem cells. There is a strong
correlation between progressive malignancy and loss in sensitivity
towards the negative regulation of cellular proliferation TGF-b in
tumour cells, which is often due to mutational inactivation or
decreased TGF-b receptor function (de Caestecker et al, 2000;
Kim et al, 2000). In addition tumour cells often escape from the
anti-proliferative effects of TGF-b by mutation or disregulated
expression of components in its signalling pathway (Yanagisawa
et al, 2000). These publications suggest that TGF-b2 could be given
safely during anti-tumour therapy. In conclusion, the present
results indicate that oral supplementation of bovine TGF-b2
enriched milk fraction might prove useful in ameliorating the
complications of anti-cancer therapy in humans with TGF-b2
unresponsive tumour cells.
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Figure 5 Weight loss due to MTX toxicity is reduced by supplementa-
tion of TGF-b2 enriched fraction. Effect of MTX on the weight of rats is
shown as per cent of weight on day 0 (mean+s.d.). The arrows located
on the X-axis indicate the two MTX injections. Two groups of rats treated
with or without MTX are shown in triangles and squares respectively, in
which the closed symbols represent groups supplemented with TGF-b2
enriched fraction. *Indicates signiﬁcant differences between the MTX trea-
ted group receiving placebo and the other groups. (P50.01).
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